Data as of Mar 11
| -0.50 / -1.83%|
The 10 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 23.00, with a high estimate of 36.00 and a low estimate of 10.00. The median estimate represents a -14.15% decrease from the last price of 26.79.
The current consensus among 13 polled investment analysts is to Hold stock in Sarepta Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.